Thyroid cancer is frequently associated with the oncogenic conversion of such proteins as the receptor tyrosine kinases (RTK) RET and NTRK1, or RAS, BRAF, and PI3KCA that act in the ERK or the phosphatidylinositol- 3 kinase (PI3K) signaling cascades. These oncogenic pathways, in turn, sustain neo-angiogenesis, loss of differentiation, autonomous proliferation, and invasion (24). Therefore, investigators are focusing on these cascades in an attempt to identify new agents to treat thyroid cancers that are resistant to or not appropriate for adjuvant treatment with radioactive iodine. This commentary discusses preclinical evidences supporting a role for oncogenic kinases targeting in the molecular therapy of thyroid cancer.
Pros and cons of cellular studies in developing new drugs for thyroid cancers / Salvatore, G.; Carlomagno, Francesca; Santoro, Massimo. - In: THYROID. - ISSN 1050-7256. - STAMPA. - 18:8(2008), pp. 819-822. [10.1089/thy.2008.1541]
Pros and cons of cellular studies in developing new drugs for thyroid cancers
CARLOMAGNO, Francesca;SANTORO, MASSIMO
2008
Abstract
Thyroid cancer is frequently associated with the oncogenic conversion of such proteins as the receptor tyrosine kinases (RTK) RET and NTRK1, or RAS, BRAF, and PI3KCA that act in the ERK or the phosphatidylinositol- 3 kinase (PI3K) signaling cascades. These oncogenic pathways, in turn, sustain neo-angiogenesis, loss of differentiation, autonomous proliferation, and invasion (24). Therefore, investigators are focusing on these cascades in an attempt to identify new agents to treat thyroid cancers that are resistant to or not appropriate for adjuvant treatment with radioactive iodine. This commentary discusses preclinical evidences supporting a role for oncogenic kinases targeting in the molecular therapy of thyroid cancer.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
